97664-53-4

Upstream product

• 629-11-8 1,6-hexanediol 
• 65512-08-5 4-phenylbutyl methanesulfonate 
• 13633-25-5 1-Bromo-4-phenylbutane 
• 3360-41-6 4-phenyl-butan-1-ol 

Downstream Products

• 97664-55-6 N-[6-(4-phenylbutoxy)hexyl]benzenemethanamine 
• 135235-81-3 6-(4-phenylbutyloxy)hexyl methanesulfonate 
• 380414-69-7 (1R,1'S)-1-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-2-{(2-hydroxy-1-phenyl-ethyl)-[6-(4-phenyl-butoxy)-hexyl]-amino}-ethanol 
• 135271-47-5 (R)-(-)-salmeterol 
• 97664-54-5 6-(4-phenylbutoxy)hexanal 

Relevant academic research and scientific papers

Crystal of fumarate of salmeterol intermediate and preparation process thereof

The invention discloses a crystal of fumarate of a salmeterol intermediate and a preparation process thereof. The preparation process comprises the following steps: dissolving 6-benzylamino-1-(4'-phenylbutoxy)hexane in alcohol; adding fumaric acid; carrying out heating to 50 to 60 DEG C and carrying out stirring to allow the above substance to be thoroughly dissolved; carrying out cooling to 37 to 40 DEG C within 2 to 4 h so as to allow a crystal to be precipitated, and maintaining the temperature for 2 to 3 h; then allowing the temperature to drop to 12 to 15 DEG C within 6 to 8 h; and successively carrying out ageing for 8 to 12 h, filtering and drying so as to obtain a white solid so as to obtain the fumarate of the salmeterol intermediate 6-benzylamino-1-(4'-phenylbutoxy)hexane. The crystal obtained in the invention has good stability and can be stored for a long time; the preparation process is convenient to operate and easy for industrialization; the alcohol used in the invention is a low-toxicity solvent selected from an organic solvent; and the crystal form of the fumarate of the salmeterol intermediate can be stably obtained.

Synthesis of the β2 Agonist (R)-Salmeterol Using a Sequence of Supported Reagents and Scavenging Agents

(Matrix Presented) The enantioselective synthesis of (R)-salmeterol has been achieved by using a sequence of supported reagents and sequestering agents. The saligenin core was installed by a regiospecific alkylation and a chiral auxiliary approach was employed to introduce the desired stereochemistry via a diastereoselective reduction.